

2019 Future of Cancer related Pain R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2A39EE18E84EN.html>

Date: February 2019

Pages: 110

Price: US\$ 2,199.00 (Single User License)

ID: 2A39EE18E84EN

Abstracts

The global demand for Cancer related Pain treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Cancer related Pain pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Cancer related Pain pipeline companies from advancing their products into Phase 3 or Phase 4.

Cancer related Pain Report Description-

The 2019 pipeline study on Cancer related Pain pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Cancer related Pain pipeline compounds.

The Cancer related Pain pipeline guide presents information on all active drugs currently being developed for Cancer related Pain. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Cancer related Pain pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Cancer related Pain drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Cancer related Pain product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Cancer related Pain pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Cancer related Pain pipeline report includes-

An overview of Cancer related Pain disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Cancer related Pain pipeline

Company wise list of Cancer related Pain pipeline

Mechanism of Action wise Cancer related Pain pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Cancer related Pain pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Cancer related Pain pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Cancer related Pain pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL CANCER RELATED PAIN PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Cancer related Pain Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Cancer related Pain pipeline, H1- 2019
- 3.5 Mechanism of Action wise Cancer related Pain Pipeline Candidates

4 ALEXZA PHARMACEUTICALS INC CANCER RELATED PAIN PIPELINE DETAILS

- 4.1 Alexza Pharmaceuticals Inc Business Profile
- 4.2 Alexza Pharmaceuticals Inc Cancer related Pain Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ANGIOCHEM INC CANCER RELATED PAIN PIPELINE DETAILS

- 5.1 AngioChem Inc Business Profile
- 5.2 AngioChem Inc Cancer related Pain Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 AOXING PHARMACEUTICAL COMPANY INC CANCER RELATED PAIN PIPELINE DETAILS

- 6.1 Aoxing Pharmaceutical Company Inc Business Profile
- 6.2 Aoxing Pharmaceutical Company Inc Cancer related Pain Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 APHIOS CORP CANCER RELATED PAIN PIPELINE DETAILS

- 7.1 Aphios Corp Business Profile
- 7.2 Aphios Corp Cancer related Pain Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 AQUILUS PHARMACEUTICALS INC CANCER RELATED PAIN PIPELINE DETAILS

- 8.1 Aquilus Pharmaceuticals Inc Business Profile
- 8.2 Aquilus Pharmaceuticals Inc Cancer related Pain Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 ASTRAZENECA PLC CANCER RELATED PAIN PIPELINE DETAILS

- 9.1 AstraZeneca Plc Business Profile

9.2 AstraZeneca Plc Cancer related Pain Drug Details

9.3 Drug Snapshot

9.3.1 Originator

9.3.2 Collaborator/Co-Developer

9.3.3 Route of Administration

9.3.4 Orphan Drug/Fast Track/Special Designation

9.3.5 Geography

9.3.6 Type of Molecular Entity

9.3.7 Current Status

9.4 Drug Overview

9.5 Drug Mechanism of Action

9.6 Clinical/Pre-clinical Trial Details

9.7 Latest Drug Developments

10 CONCENTRIC ANALGESICS INC CANCER RELATED PAIN PIPELINE DETAILS

10.1 Centric Analgesics Inc Business Profile

10.2 Centric Analgesics Inc Cancer related Pain Drug Details

10.3 Drug Snapshot

10.3.1 Originator

10.3.2 Collaborator/Co-Developer

10.3.3 Route of Administration

10.3.4 Orphan Drug/Fast Track/Special Designation

10.3.5 Geography

10.3.6 Type of Molecular Entity

10.3.7 Current Status

10.4 Drug Overview

10.5 Drug Mechanism of Action

10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

11 DAEWOONG PHARMACEUTICAL CO LTD CANCER RELATED PAIN PIPELINE DETAILS

11.1 Daewoong Pharmaceutical Co Ltd Business Profile

11.2 Daewoong Pharmaceutical Co Ltd Cancer related Pain Drug Details

11.3 Drug Snapshot

11.3.1 Originator

11.3.2 Collaborator/Co-Developer

- 11.3.3 Route of Administration
- 11.3.4 Orphan Drug/Fast Track/Special Designation
- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 DOMPE FARMACEUTICI SPA CANCER RELATED PAIN PIPELINE DETAILS

- 12.1 Dompe Farmaceutici SpA Business Profile
- 12.2 Dompe Farmaceutici SpA Cancer related Pain Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 FUJIMOTO PHARMACEUTICAL CORP CANCER RELATED PAIN PIPELINE DETAILS

- 13.1 Fujimoto Pharmaceutical Corp Business Profile
- 13.2 Fujimoto Pharmaceutical Corp Cancer related Pain Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity

- 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 HISAMITSU PHARMACEUTICAL CO INC CANCER RELATED PAIN PIPELINE DETAILS

- 14.1 Hisamitsu Pharmaceutical Co Inc Business Profile
- 14.2 Hisamitsu Pharmaceutical Co Inc Cancer related Pain Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 IMMUPHARMA PLC CANCER RELATED PAIN PIPELINE DETAILS

- 15.1 Immupharma Plc Business Profile
- 15.2 Immupharma Plc Cancer related Pain Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16 INDIA GLOBALIZATION CAPITAL CANCER RELATED PAIN PIPELINE DETAILS

16.1 India Globalization Capital Business Profile

16.2 India Globalization Capital Cancer related Pain Drug Details

16.3 Drug Snapshot

16.3.1 Originator

16.3.2 Collaborator/Co-Developer

16.3.3 Route of Administration

16.3.4 Orphan Drug/Fast Track/Special Designation

16.3.5 Geography

16.3.6 Type of Molecular Entity

16.3.7 Current Status

16.4 Drug Overview

16.5 Drug Mechanism of Action

16.6 Clinical/Pre-clinical Trial Details

16.7 Latest Drug Developments

17 KLARIA PHARMA HOLDING AB CANCER RELATED PAIN PIPELINE DETAILS

17.1 Klaria Pharma Holding AB Business Profile

17.2 Klaria Pharma Holding AB Cancer related Pain Drug Details

17.3 Drug Snapshot

17.3.1 Originator

17.3.2 Collaborator/Co-Developer

17.3.3 Route of Administration

17.3.4 Orphan Drug/Fast Track/Special Designation

17.3.5 Geography

17.3.6 Type of Molecular Entity

17.3.7 Current Status

17.4 Drug Overview

17.5 Drug Mechanism of Action

17.6 Clinical/Pre-clinical Trial Details

17.7 Latest Drug Developments

18 KOMIPHARM INTERNATIONAL CO LTD CANCER RELATED PAIN PIPELINE DETAILS

- 18.1 Komipharm International Co Ltd Business Profile
- 18.2 Komipharm International Co Ltd Cancer related Pain Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer
 - 18.3.3 Route of Administration
 - 18.3.4 Orphan Drug/Fast Track/Special Designation
 - 18.3.5 Geography
 - 18.3.6 Type of Molecular Entity
 - 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 MEDLAB CLINICAL LTD CANCER RELATED PAIN PIPELINE DETAILS

- 19.1 Medlab Clinical Ltd Business Profile
- 19.2 Medlab Clinical Ltd Cancer related Pain Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 NANOMERICS LTD CANCER RELATED PAIN PIPELINE DETAILS

- 20.1 Nanomerics Ltd Business Profile
- 20.2 Nanomerics Ltd Cancer related Pain Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer

- 20.3.3 Route of Administration
- 20.3.4 Orphan Drug/Fast Track/Special Designation
- 20.3.5 Geography
- 20.3.6 Type of Molecular Entity
- 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 NEUROCENTRX PHARMA LTD CANCER RELATED PAIN PIPELINE DETAILS

- 21.1 Neurocentrx Pharma Ltd Business Profile
- 21.2 Neurocentrx Pharma Ltd Cancer related Pain Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 NIPPON ZOKI PHARMACEUTICAL CO LTD CANCER RELATED PAIN PIPELINE DETAILS

- 22.1 Nippon Zoki Pharmaceutical Co Ltd Business Profile
- 22.2 Nippon Zoki Pharmaceutical Co Ltd Cancer related Pain Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity

- 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 OBLIQUE THERAPEUTICS AB CANCER RELATED PAIN PIPELINE DETAILS

- 23.1 Oblique Therapeutics AB Business Profile
- 23.2 Oblique Therapeutics AB Cancer related Pain Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 ORION CORP CANCER RELATED PAIN PIPELINE DETAILS

- 24.1 Orion Corp Business Profile
- 24.2 Orion Corp Cancer related Pain Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25 PFIZER INC CANCER RELATED PAIN PIPELINE DETAILS

- 25.1 Pfizer Inc Business Profile
- 25.2 Pfizer Inc Cancer related Pain Drug Details
- 25.3 Drug Snapshot
 - 25.3.1 Originator
 - 25.3.2 Collaborator/Co-Developer
 - 25.3.3 Route of Administration
 - 25.3.4 Orphan Drug/Fast Track/Special Designation
 - 25.3.5 Geography
 - 25.3.6 Type of Molecular Entity
 - 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26 PHARMALEADS SA CANCER RELATED PAIN PIPELINE DETAILS

- 26.1 Pharmaleads SA Business Profile
- 26.2 Pharmaleads SA Cancer related Pain Drug Details
- 26.3 Drug Snapshot
 - 26.3.1 Originator
 - 26.3.2 Collaborator/Co-Developer
 - 26.3.3 Route of Administration
 - 26.3.4 Orphan Drug/Fast Track/Special Designation
 - 26.3.5 Geography
 - 26.3.6 Type of Molecular Entity
 - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27 PLEXXIKON INC CANCER RELATED PAIN PIPELINE DETAILS

- 27.1 Plexxikon Inc Business Profile
- 27.2 Plexxikon Inc Cancer related Pain Drug Details

- 27.3 Drug Snapshot
 - 27.3.1 Originator
 - 27.3.2 Collaborator/Co-Developer
 - 27.3.3 Route of Administration
 - 27.3.4 Orphan Drug/Fast Track/Special Designation
 - 27.3.5 Geography
 - 27.3.6 Type of Molecular Entity
 - 27.3.7 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28 RECORDATI SPA CANCER RELATED PAIN PIPELINE DETAILS

- 28.1 Recordati SpA Business Profile
- 28.2 Recordati SpA Cancer related Pain Drug Details
- 28.3 Drug Snapshot
 - 28.3.1 Originator
 - 28.3.2 Collaborator/Co-Developer
 - 28.3.3 Route of Administration
 - 28.3.4 Orphan Drug/Fast Track/Special Designation
 - 28.3.5 Geography
 - 28.3.6 Type of Molecular Entity
 - 28.3.7 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

29 RIBOMIC INC CANCER RELATED PAIN PIPELINE DETAILS

- 29.1 Ribomic Inc Business Profile
- 29.2 Ribomic Inc Cancer related Pain Drug Details
- 29.3 Drug Snapshot
 - 29.3.1 Originator
 - 29.3.2 Collaborator/Co-Developer
 - 29.3.3 Route of Administration
 - 29.3.4 Orphan Drug/Fast Track/Special Designation

- 29.3.5 Geography
- 29.3.6 Type of Molecular Entity
- 29.3.7 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action
- 29.6 Clinical/Pre-clinical Trial Details
- 29.7 Latest Drug Developments

30 SEDOR PHARMACEUTICALS LLC CANCER RELATED PAIN PIPELINE DETAILS

- 30.1 Sedor Pharmaceuticals LLC Business Profile
- 30.2 Sedor Pharmaceuticals LLC Cancer related Pain Drug Details
- 30.3 Drug Snapshot
 - 30.3.1 Originator
 - 30.3.2 Collaborator/Co-Developer
 - 30.3.3 Route of Administration
 - 30.3.4 Orphan Drug/Fast Track/Special Designation
 - 30.3.5 Geography
 - 30.3.6 Type of Molecular Entity
 - 30.3.7 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31 SORRENTO THERAPEUTICS INC CANCER RELATED PAIN PIPELINE DETAILS

- 31.1 Sorrento Therapeutics Inc Business Profile
- 31.2 Sorrento Therapeutics Inc Cancer related Pain Drug Details
- 31.3 Drug Snapshot
 - 31.3.1 Originator
 - 31.3.2 Collaborator/Co-Developer
 - 31.3.3 Route of Administration
 - 31.3.4 Orphan Drug/Fast Track/Special Designation
 - 31.3.5 Geography
 - 31.3.6 Type of Molecular Entity
 - 31.3.7 Current Status
- 31.4 Drug Overview

- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

32 TETRA BIO-PHARMA INC CANCER RELATED PAIN PIPELINE DETAILS

- 32.1 Tetra Bio-Pharma Inc Business Profile
- 32.2 Tetra Bio-Pharma Inc Cancer related Pain Drug Details
- 32.3 Drug Snapshot
 - 32.3.1 Originator
 - 32.3.2 Collaborator/Co-Developer
 - 32.3.3 Route of Administration
 - 32.3.4 Orphan Drug/Fast Track/Special Designation
 - 32.3.5 Geography
 - 32.3.6 Type of Molecular Entity
 - 32.3.7 Current Status
- 32.4 Drug Overview
- 32.5 Drug Mechanism of Action
- 32.6 Clinical/Pre-clinical Trial Details
- 32.7 Latest Drug Developments

33 VIROBAY INC CANCER RELATED PAIN PIPELINE DETAILS

- 33.1 Virobay Inc Business Profile
- 33.2 Virobay Inc Cancer related Pain Drug Details
- 33.3 Drug Snapshot
 - 33.3.1 Originator
 - 33.3.2 Collaborator/Co-Developer
 - 33.3.3 Route of Administration
 - 33.3.4 Orphan Drug/Fast Track/Special Designation
 - 33.3.5 Geography
 - 33.3.6 Type of Molecular Entity
 - 33.3.7 Current Status
- 33.4 Drug Overview
- 33.5 Drug Mechanism of Action
- 33.6 Clinical/Pre-clinical Trial Details
- 33.7 Latest Drug Developments

34 WEX PHARMACEUTICALS INC CANCER RELATED PAIN PIPELINE DETAILS

- 34.1 WEX Pharmaceuticals Inc Business Profile
- 34.2 WEX Pharmaceuticals Inc Cancer related Pain Drug Details
- 34.3 Drug Snapshot
 - 34.3.1 Originator
 - 34.3.2 Collaborator/Co-Developer
 - 34.3.3 Route of Administration
 - 34.3.4 Orphan Drug/Fast Track/Special Designation
 - 34.3.5 Geography
 - 34.3.6 Type of Molecular Entity
 - 34.3.7 Current Status
- 34.4 Drug Overview
- 34.5 Drug Mechanism of Action
- 34.6 Clinical/Pre-clinical Trial Details
- 34.7 Latest Drug Developments

35. LATEST CANCER RELATED PAIN DRUG PIPELINE DEVELOPMENTS, 2019

36. APPENDIX

- 36.1 About Us
- 36.2 Sources and Methodology
- 36.3 Contact Information

I would like to order

Product name: 2019 Future of Cancer related Pain R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2A39EE18E84EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2A39EE18E84EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

